Nile Therapeutics, Inc. Share Price Other OTC
Equities
US6541451018
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-17 | Oppenheimer Initiates Capricor Therapeutics at Outperform Rating | MT |
05-13 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Sales 2024 * | 26.58M 2.09B | Sales 2025 * | 78.61M 6.18B | Capitalization | 177M 13.88B |
---|---|---|---|---|---|
Net income 2024 * | -33M -2.59B | Net income 2025 * | -4M -315M | EV / Sales 2024 * | 6.64 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.25 x |
P/E ratio 2024 * |
-5.36
x | P/E ratio 2025 * |
-24.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.74% |
Latest transcript on Nile Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 19/11/13 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 19/11/13 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 20/07/23 |
Earl Collier
BRD | Director/Board Member | 76 | 19/11/13 |
George Dunbar
BRD | Director/Board Member | 77 | 19/11/13 |
1st Jan change | Capi. | |
---|---|---|
+8.92% | 114B | |
+10.48% | 105B | |
-2.68% | 21.73B | |
-6.45% | 23.83B | |
-10.58% | 18.1B | |
-42.36% | 16.34B | |
-14.45% | 16.13B | |
+3.76% | 13.75B | |
+28.94% | 11.76B |